Bio-Techne logged a -1.5% change during today's afternoon session, and is now trading at a price of $77.5 per share. The S&P 500 index moved 1.0%. TECH's trading volume is 552,677 compared to the stock's average volume of 1,005,084.
Bio-Techne trades -23.32% away from its average analyst target price of $101.07 per share. The 13 analysts following the stock have set target prices ranging from $88.0 to $120.0, and on average have given Bio-Techne a rating of buy.
If you are considering an investment in TECH, you'll want to know the following:
-
Bio-Techne's current price is 337.7% above its Graham number of $17.7, which implies that at its current valuation it does not offer a margin of safety
-
Bio-Techne has moved -2.9% over the last year, and the S&P 500 logged a change of 16.2%
-
Based on its trailing earnings per share of 1.68, Bio-Techne has a trailing 12 month Price to Earnings (P/E) ratio of 46.1 while the S&P 500 average is 15.97
-
TECH has a forward P/E ratio of 32.2 based on its forward 12 month price to earnings (EPS) of $2.41 per share
-
The company has a price to earnings growth (PEG) ratio of 3.73 — a number near or below 1 signifying that Bio-Techne is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 6.45 compared to its sector average of 4.16
-
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.
-
Based in Minneapolis, the company has 3,000 full time employees and a market cap of $12.2 Billion. Bio-Techne currently returns an annual dividend yield of 0.4%.